- Experimental drug Zorevunersen shows seizure reduction in Dravet syndrome trial
- Study involved 81 children with treatment-resistant genetic epilepsy
- Seizures fell about 50% after dose, up to 80% after three doses
- Researchers plan phase 3 trial to confirm safety and effectiveness
Research workers have also taken some promising preliminary signs with a new experimental medication that might revolutionize the therapy of children who are living with Dravet syndrome which is a severe type of epilepsy, and it is quite often hard to cure via the use of conventional medications. Early clinical trials of a drug called Zorevunersen indicate that Zorevunersen has a high potential to reduce the level of seizures and increase the quality of life in young patients.
The results were of the research conducted by scientists at the University College London and the Great Ormond Street Hospital where the results were announced in the The New England Journal of Medicine. According to researchers, the preclinical trial on the therapy has revealed that it may treat the root cause of the disorder, instead of treating its symptoms. Dravet syndrome is a neurological disorder that is rare and results due to mutations in the SCN1A gene and it usually starts at infancy.
It is marked with severe frequent seizures and developmental delays, speech problems and behavioral issues. The number of individuals affected by the condition in the United Kingdom is as high as 3,000 as experts estimate. The contemporary therapies are largely aimed at addressing epilepsy by managing the seizure situations with both or a mix of anti-epileptic drugs, yet most of the affected patients still report recurrence of the instances despite medication. Trial Results indicate that there is a great deal of reduction on the number of seizures.
Eighty-one children with epilepsy treatment-resistant amid the range of two to 18 years were recruited into the clinical trial related to Dravet syndrome. The children had 17 average seizures per month prior to inclusion into the study. Seizure frequency reduced about 50 percent on average after Zorevunersen had been given 70 milligrams. In a number of participants, the number of seizures came down by a third after three doses.
Other gains reported by researchers were beyond seizure control to motor functions, communication skills and level of daily activity. Professor Helen Cross, director of childhood epilepsy at the UCL Institute of Child Health and honorary consultant at the Great Ormond Street Hospital, commented the findings could be a significant advance to families living with the condition.
Cross commonly encounters patients with the hard-to-treat genetic epilepsies, which may experience several seizures a week. The situation is that many of them cannot do anything independently on their own; they need around the clock assistance and a high risk of the sudden expected death in epilepsy. She indicated that in case the drug is effective as confirmed by subsequent trials, it would change the results of the treatment of the affected children. Should the phase 3 experiments prove effective, this new treatment would allow children with Dravet syndrome to lead more healthy and normal lives.
Scholars Hail Outcomes as a Their Great Leap Forward
Research findings According to epilepsy experts not taking part in the study, the results form a major breakthrough in the quest to identify treatments of genetic causes of epilepsy. The outcomes of the trial provide the potentially new generation of treatments, as Jowinn Chew, the head of research of the charity Young Epilepsy said. Early findings denote that the initial outcomes were a clinical breakthrough in a new direction where a future cure addresses the root cause of Dravet syndrome and not just coping with it, according to Chew.
Dr Alfredo Gonzalez-Sulser was optimistic that the therapy would open the door to treatment of an expanded range of genetic epilepsies. Viewed currently, he said that there are more than 800 genetic epilepsies that required therapeutics comparable to Zorevunersen. This establishes a clear direction that would result in effective interventions of these debilitating life-altering diseases on both the patient and the care-takers.
According to Professor Deb Pal, "the study was a milestone to families with genetic epilepsies". In their landmark study, Pal said that "the parents of thousands of children and young people with monogenic epilepsies around the world have been given substantial hope."
Next Phase Of Research
Despite positive initial outcomes, scientists make it clear that it is necessary to conduct additional studies to verify the safety and efficacy of the medication over the long term. It will consist of a big Phase 3 clinical trial to test the treatment with a long term period, scrutinize any rare side effects and identify the patients who are most likely to be responded to.
These are necessary trials that would help the regulatory agencies to be able to consider the approval of the therapy to be used widely. Scientists also hope that the research may result in the same genetic cures to other neurological illnesses.
The results indicate that there is an increased trend of investigations of epilepsy in relation to interventions that address the underlying genetic pathogenesis as opposed to the introduction of interventions based on pharmacological methods for managing the disease symptoms. Additional information on the study is available in the original report in The New England Journal of Medicine as well as in that of The Guardian.
